Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators

Publisher: Bentham Science Publishers

E-ISSN: 1873-4286|22|10|1312-1323

ISSN: 1381-6128

Source: Current Pharmaceutical Design, Vol.22, Iss.10, 2016-03, pp. : 1312-1323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Neurodegenerative disorders are one of the most critical public health concerns of our times. Regrettably, therapeutic interventions currently available have shown only partial benefits to patients affected by one of these disorders. Although the important advances made during the last decades, several questions regarding physiopathological aspects of these diseases are still open. On this regard, the role of neuroinflammation is recognized as critical during the establishment and progression of the neurodegenerative process, and several authors have suggested that neuroinflammatory modulation should be at the basis of therapeutic treatment. In the present review we summarize the general aspects of the neuroinflammatory process and the cellular component of such response whose have been commonly related with the main neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease, as well as, the main molecular events that might trigger the inflammatory process and affect neuronal support structures, such as the blood brain barrier, leading to neurodegeneration. Additionally, we discuss recent advances regarding Nuclear Receptors research, such as peroxisome proliferators-activated receptors and liver X receptor, and the molecular basis of its potential role against neuroinflammation and neurodegeneration.